Summary results across all cancer sites for cancer related outcomes
| Cancer site (no of audits included in analyses/no included in review)† | Proportion of 2WW referrals among patients diagnosed with cancer | Cancer detection rates‡ | Cancer detection rates among non-2WW referrals (not all of which were GP referrals) | Cancer detection rates for 2WW referrals in line with guidelines | Cancer detection rates for 2WW referrals not in line with guidelines |
|---|---|---|---|---|---|
| 2WW, 2 week wait. | |||||
| *Some of the percentages reported are based on a very small number of patients (<10). | |||||
| †The audits included in the analyses (and therefore reported in this table) only include those that reported minimal data on how eligible patients were identified or the data source and reported separate results for individual cancer sites. | |||||
| ‡Cancer detection rates among 2WW referrals (2WWR) or among referrals considered “urgent” by hospital (Hospital). | |||||
| Brain and CNS (12/12) | – | 2WWR: 0–15% (8 audits)* | – | – | – |
| Breast (59/72) | 4–83% (9 audits) | 2WWR: 0–34% (37 audits)Hospital: 16–50% (3 audits) | Urgent non-2WW: 4–20% (5 audits)Non-urgent: 0–10% (18 audits) | 16% (1 audit) | 0% (1 audit) |
| Children (9/9) | – | 2WWR: 0% (3 audits)* | – | – | – |
| Lower GI (47/71) | 0–46% (7 audits)* | 2WWR: 2–22% (30 audits) | All non-2WW: 9%; urgent non-2WW: 21% (1 audit)Urgent non-2WW: 14% (1 audit)With 2WW symptoms: 6%; without 2WW symptoms: 1% (1 audit) | 12–21% (2 audits) | 0–3% (3 audits) |
| Upper GI (36/54) | 0–40% (9 audits)* | 2WWR: 0–30% (23 audits)*Hospital: 5% (1 audit) | Non-urgent: 2% (1 audit) | – | 9% (1 audit) |
| Gynaecological (36/45) | 0–34% (8 audits)* | 2WWR: 0–25% (18 audits)* | – | 15% (1 audit) | 0–4% (3 audits)* |
| Haematological (21/26) | 0–25% (3 audits)* | 2WWR: 0–75% (10 audits)* | Non-2WW: 19% (1 audit) | 25% (1 audit) | – |
| Head and neck (23/30) | 0–25% (4 audits)* | 2WWR: 0–18% (14 audits)* | Urgent non-2WW: 1% (1 audit) | – | 7–20% (2 audits)* |
| Lung (33/43) | 0–57% (5 audits)* | 2WWR: 5–75% (15 audits)* | Non-2WW: 62% (1 audit)Routine: 2% (1 audit) | 51% (1 audit) | 0–43% (2 audits)* |
| Sarcomas (10/11) | – | 2WWR: 0–20% (7 audits)* | – | – | – |
| Skin (43/59) | 7–44% (6 audits)* | 2WWR: 2–36% (23 audits)* | All non-2WW: 25%; urgent non-2WW: 71% (1 audit) | 16% (1 audit) | 33% (1 audit) |
| Urological (34/43) | 0–100% (8 audits)* | 2WWR: 13–50% (17 audits)* | Non-2WW: 17% (1 audit; all referrals considered urgent by hospital consultant)Routine: 16% (1 audit) | – | 0% (1 audit)* |